Upadacitinib Better than Adalimumab in Rheumatoid Arthritis
A new study of AbbVie’s original JAK1-selective inhibitor indicates that it outdoes adalimumab without sacrificing safety in rheumatoid arthritis treatment.
Ixekizumab Shows Strength Against Adalimumab in SPIRIT-H2H
Ixekizumab (Talz) was significantly more likely to both reduce disease activity by ≥50% and achieve complete skin clearance than adalimumab (Humira).
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.